Aprea Therapeutics, Inc. Form 8-K Summary
Reporting date: February 6, 2024. The filing reports an update to the company’s corporate presentation and does not provide financial statements or period-specific operating results.
Business Context
Aprea Therapeutics, Inc. is a Delaware corporation with common stock trading on Nasdaq under the symbol APRE. The filing was signed by Oren Gilad, Ph.D., President and Chief Executive Officer.
Financial and Operating Metrics
The filing does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash runway, or other financial metrics.
Material Changes and Outlook
On February 6, 2024, Aprea updated its corporate presentation slide deck. The presentation is filed as Exhibit 99.1 and incorporated by reference. The filing itself does not specify changes to guidance, clinical programs, financing plans, risks, contingencies, or management outlook.
Important Facts to Verify
- Review Exhibit 99.1, the February 2024 corporate presentation, for updated pipeline, clinical, corporate, financing, and forward-looking information.
- Verify any financial or liquidity information in the company’s latest periodic filing, as this Form 8-K does not report financial results.
- Assess forward-looking statements and related risks directly in the presentation and subsequent SEC filings.